Patents Examined by Lila Feisee
  • Patent number: 5976816
    Abstract: The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: November 2, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Daniel L. Alkon, Rene Etcheberrigaray, Christopher S. Kim, Yi-Fan Han, Tom J. Nelson
  • Patent number: 5977318
    Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 2, 1999
    Assignee: Bristol Myers Squibb Company
    Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Peter A. Kiener
  • Patent number: 5977070
    Abstract: A pharmaceutical composition for the nasal delivery of compounds useful for treating osteoporosis, comprising an effective amount of a physiologically active truncated analog of PTH or PTHrp, or salt thereof, in which amino acid residues (22-31) form an amphipathic .alpha.-helix, said residues (22-31) selected from (SEQ ID NOS: 85, 86, 26, 27, 28, 29, and 30); an absorption enhancer selected from the group consisting of dimethyl-.beta.-cyclodextrin and the bile acid surfactants; and water is provided.
    Type: Grant
    Filed: August 29, 1995
    Date of Patent: November 2, 1999
    Inventors: Christin Teresa Piazza, Michael Lloyd Radomsky, John Leonard Krstenansky, John Joseph Nestor, Jr., Brian Henry Vickery
  • Patent number: 5977320
    Abstract: The present invention provides a novel human phosphorylase kinase gamma subunit (HPHKG) and the polynucleotide which identifies and encodes HPHKG. The invention provides for expression vectors and host cells comprising the nucleic acid sequence encoding HPHKG. The invention also provides pharmaceutical compositions containing purified HPHKG or antisense molecules to HPHKG for the treatment of diseases associated with expression of HPHKG. The invention also includes diagnostic compositions containing the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding HPHKG or anti-HPHKG antibodies which specifically bind to HPHKG, and the use of such compositions for diagnosis of disease.
    Type: Grant
    Filed: June 11, 1998
    Date of Patent: November 2, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Surya K. Goli
  • Patent number: 5976831
    Abstract: Soluble and membrane-bound forms of human Fc.gamma.RIII are provided, together with nucleic acids capable of encoding the same. Soluble Fc.gamma.RIIIs are useful in ameliorating the serum platelet deficiency associated with immune thrombocytopenic purpura. Cells expressing membrane-bound Fc.gamma.RIII are useful components in assays for serum immune complexes.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: November 2, 1999
    Assignee: Applied Research Systems ARS Holding, N.V.
    Inventors: Gary A. Peltz, Kevin W. Moore
  • Patent number: 5977298
    Abstract: The present invention relates to compounds represented by formula (I): ##STR1## wherein Z represents Gly or Cys; X represents an (.alpha.-amino acid residue; Y represents a natural calcitonin moiety, a partial natural calcitonin peptide moiety, or a natural calcitonin-like peptide moiety; m represents an integer of 5-8, .alpha.-amino acid residues represented by X being the same or different; and n represents an integer of 0-3; provided that when m is 5, the sequence of 4 C-terminal residues of --(X).sub.m -- is different from the sequence of the third to sixth amino acids of natural calcitonin, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: November 2, 1999
    Assignee: Kvowa Hakko Kogyo Co., Ltd.
    Inventors: Kenji Shibata, Motoo Yamasaki, Masako Hamada, Tatsuya Tamaoki, Nobuo Kosaka, Soichiro Sato
  • Patent number: 5976534
    Abstract: Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal an anti-PDGF receptor antibody, such as an anti-PDGF-alpha receptor antibody or an anti-PDGF-beta receptor antibody. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The anti-PDGF receptor antibodies may optionally be administered coordinately with heparin, whereby the coordinately administered antibody and heparin are combinatorially effective in inhibiting intimal hyperplasia.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 2, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Richard D. Kenagy, Alexander W. Clowes
  • Patent number: 5977077
    Abstract: Therapeutic compositions for the treatment of infectious diseases are disclosed. These compositions comprise xanthones and xanthone derivatives, such as 2,3,4,5,6-pentahydroxyxanthone. Also disclosed are methods for the treatment of infectious diseases using such compounds.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: November 2, 1999
    Assignee: Interlab Corporation
    Inventors: Rolf Walter Winter, Michael Kevin Riscoe, David J. Hinrichs
  • Patent number: 5976818
    Abstract: Hybridomally produced monoclonal antibodies specifically immunoreactive with the glycoprotein carrying the CA 125 epitope. Monoclonal antibodies recognize both high and low molecular weight subunits of the antigen, and identify the antigen in the cytoplasm and the extracellular matrix of CA 125 producing cells. An immunoassay for the detection of CA 125 utilizing the monoclonal antibodies is described.
    Type: Grant
    Filed: April 2, 1996
    Date of Patent: November 2, 1999
    Assignee: The Board of Trustees of The University of Arkansas
    Inventor: Timothy J. O'Brien
  • Patent number: 5972649
    Abstract: The invention provides a human multiple endocrine neoplasia type 1 protein (MEND1) and polynucleotides which identify and encode MEND1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of MEND1.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: October 26, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Peter A. Covitz, Y. Tom Tang, Lynn E. Murry
  • Patent number: 5972648
    Abstract: Disclosed are hirudin analogs, a method of manufacture thereof, and anticoagulant compositions containing the same. Sequences Asp.sup.33 -Gly.sup.34 or Asp.sup.62 -Ala.sup.63 of naturally-occurring hirudins or their analogs were substituted as disclosed to suppress the formation of succinimide- or beta- forms, thereby yielding hirudin analogs with high stability, high anti-thrombin activity, and therapeutic potential as anticoagulants. Hirudin analogs having Val.sup.1 -Val.sup.2 of naturally-occurring hirudin substituted with Ile.sup.1 -Ile.sup.2 are preferred for their high antithrombiin activity. The invention also provides DNAs encoding the amino acid sequence of hirudin analogs, expression vectors, recombinant microogranisms, and a method of manufacturing hirudin analogs using recombinant microorganisms.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: October 26, 1999
    Assignee: Japan Energy Corporation
    Inventors: Akiko Sukesada, Satoru Misawa, Hitoshi Matsuda
  • Patent number: 5972646
    Abstract: In accordance with this invention, an RPE cell membrane associated protein which has a molecular weight of about 32 kd, as determined by SDS-PAGE, has been discovered. This protein, referred to an "p32," forms an oligomeric protein complex with the previously characterized p63 protein, a component of the membrane receptor for RBP. A nucleic acid molecule which codes for the p32 protein has also been isolated and sequence analysis shows that the p32 protein belongs to the family of short chain alcohol dehydrogenases, and exhibits 11-cis retinol dehydrogenase activity, the enzyme which catalyzes conversion of 11-cis-retinol into 11-cis retinaldehyde.
    Type: Grant
    Filed: November 22, 1995
    Date of Patent: October 26, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ulf Eriksson, Andras Simon, Anna Romert
  • Patent number: 5972718
    Abstract: A method of detecting heparin-induced antibodies to complete a diagnosis of heparin-induced thrombocytopenia HITP is disclosed. In one embodiment, this method comprises binding human platelet factor 4 to a linear, non-glycosaminoglycan polymer carrying negative charges distributed along the polymer chain, wherein the negative charge carried by the polymer is less than 10 .ANG. from the polymer chain. In another embodiment, the negative charge is a strong negative charge. A complex having one or more epitopes recognizable by antibodies generated in a HITP immune response is formed. One then contacts blood plasma or serum from a human patient suspected of having HITP with the complex and analyzes the complex to determine if the HITP-related antibodies are present. In another embodiment of the invention, a kit for diagnosing HITP is disclosed.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: October 26, 1999
    Assignees: The Blood Center Research Foundation, Genetics Testing Institute
    Inventors: Manouchehr Moghaddam, Gian Visentin, Richard H. Aster, Benjamin W. Boldt
  • Patent number: 5972624
    Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising an isolated nucleic acid encoding a galanin receptor, cells comprising such vectors, antibodies directed to the galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding galanin receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid encoding a galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant galanin receptor, as well as methods of determining binding of compounds to the galanin receptor.
    Type: Grant
    Filed: April 1, 1996
    Date of Patent: October 26, 1999
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Kelli E. Smith, Christophe P. G. Gerald, Richard L. Weinshank, David Linemeyer, Theresa Branchek, Carlos Forray
  • Patent number: 5972338
    Abstract: The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5 and NL8, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: October 26, 1999
    Assignee: Genentech, Inc.
    Inventors: Paul J. Godowski, Austin L. Gurney
  • Patent number: 5968510
    Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: October 19, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Peter A. Kiener
  • Patent number: 5968752
    Abstract: Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features, and various other data characterizing morphogen cell surface receptors, particularly OP-1-binding cell surface receptors, e.g., ALK-1; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods for identifying novel morphogen receptors and their encoding DNAs; (4) methods for identifying compounds capable of modulating endogenous morphogen receptor levels; and (5) methods and compositions for identifying and producing morphogen analogs useful in the design of morphogen agonists and antagonists for therapeutic, diagnostic, and experimental uses.
    Type: Grant
    Filed: August 13, 1996
    Date of Patent: October 19, 1999
    Assignees: Creative BioMolecules, Inc., The Ludwig Institute for Cancer Research
    Inventors: Hidenori Ichijo, Hideki Nishitoh, Kuber T. Sampath
  • Patent number: 5965180
    Abstract: Shaped, unbaked dough products are provided that are coated with a glaze comprising an amount of water, a reducing sugar and a hydrophilic colloid. When baked, the dough products produce a finished product with increased horizontal dimensions over that which would be expected based on the raw dimensions of the unbaked dough product.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: October 12, 1999
    Assignee: The Pillsbury Company
    Inventor: Dennis Lonergan
  • Patent number: 5965704
    Abstract: Novel class II cytokine receptor polypeptides, polynucleotides encoding the polypeptides, an related compositions and methods are disclosed. Th polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in pancreas, small intestine, colon and thymus. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of these organs.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: October 12, 1999
    Assignee: ZymoGenetics, Inc.
    Inventors: Si Lok, Robyn L Adams, Anna C. Jelmberg, Theodore E. Whitmore, Theresa M. Farrah
  • Patent number: 5965693
    Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.
    Type: Grant
    Filed: May 19, 1997
    Date of Patent: October 12, 1999
    Assignee: Genetics Institute, Inc.
    Inventors: Kenneth Jacobs, John M. McCoy, Edward R. LaVallie, Lisa A. Racie, David Merberg, Maurice Treacy, Cheryl Evans